ID
43686
Description
A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations; ODM derived from: https://clinicaltrials.gov/show/NCT00148512
Lien
https://clinicaltrials.gov/show/NCT00148512
Mots-clés
Versions (2)
- 20/11/2016 20/11/2016 -
- 20/09/2021 20/09/2021 -
Téléchargé le
20 septembre 2021
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Parkinson Disease NCT00148512
Eligibility Parkinson Disease NCT00148512
- StudyEvent: Eligibility
Similar models
Eligibility Parkinson Disease NCT00148512
- StudyEvent: Eligibility
C0030567 (UMLS CUI [2])
C0178602 (UMLS CUI [1,2])
C0439511 (UMLS CUI [1,3])
C0205360 (UMLS CUI [1,4])
C0449238 (UMLS CUI [1,2])
C0332173 (UMLS CUI [1,3])
C1542147 (UMLS CUI [1,2])
C0205494 (UMLS CUI [1,2])
C0205487 (UMLS CUI [1,3])
C0030567 (UMLS CUI [2])
C0497327 (UMLS CUI [3])
C0451306 (UMLS CUI [4])
C0033975 (UMLS CUI [5])
C0270287 (UMLS CUI [6])
C0270288 (UMLS CUI [7])
C0205476 (UMLS CUI [1,2])
C0522055 (UMLS CUI [2])
C0020649 (UMLS CUI [3])
C0740482 (UMLS CUI [4])
C0438215 (UMLS CUI [5])
C1565489 (UMLS CUI [6,1])
C0205082 (UMLS CUI [6,2])
C0205464 (UMLS CUI [1,2])
C0036579 (UMLS CUI [2])
C0003289 (UMLS CUI [3,1])
C1524063 (UMLS CUI [3,2])
C0205272 (UMLS CUI [3,3])
C0242702 (UMLS CUI [4])
C0013227 (UMLS CUI [5,1])
C0242702 (UMLS CUI [5,2])
C0332256 (UMLS CUI [5,3])